On this episode of "Halteres Presents", hosts Mickey Urdea and Rich Thayer are sitting down with Dr. Daniel (Niels) van der Lelie, the CEO & CSO for Gusto Global, the Microbiome Ecology Company™, to cover the work that's being done to decipher the complex relationship between the gut microbiome and the human host, the methods being utilized to manipulate the composition of the gut microbiome, and the microbiome-based technologies which may allow for early detection of cancerous tumors. It's a fascinating new field of study which could potentially yield massive returns on human health outcomes. Please enjoy this episode of "Halteres Presents".

Dr. Daniel van der Lelie has worked for the last ten years in a senior management role in pharma-oriented biotechnology, agriculture, environmental sciences and on the interphase between biological sciences and nanotechnology. At Brookhaven National Laboratory he was the founder of the microbiology group, and the co-founder of the group for bioinspired assembly of nanomaterials. In 2011 he founded the Center for Agriculture and Environmental Biotechnology at Research Triangle Institute, and built an asset portfolio that led to the Center’s acquisition in 2013 by FMC Corporation, where he assumed the role of Global Director of Ag BioSolutions R&D. After leaving FMC in June 2016, he cofounded and became the Chief Scientific Officer of Gusto Global, a startup company that is developing microbiome-based next-generation immune therapeutics for modulation of the immune system. As Gusto’s Chief Scientific Office, Dr. van der Lelie focused the company’s efforts on two major programs driven by insights in the gut microbiome: immune oncology and inflammation.
Since becoming Gusto’s Chief Scientific Officer, he has played a critical role in defining Gusto’s strategic vision, and to translate this into an action plan that is successfully being implemented to develop Gusto’s core facilities and technology platforms, create strategic partnerships with academic and commercial entities, define and license technologies, build an IP portfolio, and to obtain startup funding from VC and strategic investors.
His research has resulted in more than 150 publications in peer reviewed journals, including PLoS ONE, PLoS Genetics, Nature, Nature Chemistry, Nature Nanotechnology and Nature Biotechnology, and 27 patents / patent applications, including seven recent ones assigned to Gusto Global that describe the design and use of microbiome-based LBPs to improve treatment options and clinical outcomes for patients. He has also become an invited speaker to present Gusto’s vision and breakthrough research in the microbiome space at leading international conferences.

This episode of "Halteres Presents" is brought to you by the UC San Diego Division of Extended Studies, where courses are designed for professionals looking to deepen their expertise in the biotech space. Their core course, In Vitro Diagnostics Product Development, offers a practical, end-to-end look at taking an IVD product from concept to regulatory approval. You’ll learn about product requirements, assay development, instrumentation, risk analysis, and key clinical and regulatory considerations. Learn more about the In Vitro Diagnostics Product Development course ⁠⁠HERE⁠⁠.

You can also broaden your skills with their Precision Medicine and Companion Diagnostics course, which covers biomarker-driven development, CDx/therapeutic co-development, and the expanding role of precision medicine. Learn more about the Precision Medicine and Companion Diagnostics course ⁠⁠HERE⁠⁠.

Use our exclusive discount code HALTERES10 at checkout for 10% off the price of your enrollment.

Advance your diagnostics career with UC San Diego Extended Studies - your next step in biotech starts here.

Learn more about Halteres Associates ⁠⁠⁠⁠⁠⁠⁠⁠⁠HERE⁠⁠⁠⁠⁠⁠⁠⁠⁠.